https://www.selleckchem.com/products/r-gne-140.html 17 (0.10, 0.23) cm]. For 1RM strength, each condition changed equivalently. Experiment 2 (n=18) for MT, the posterior probabilities favoured the hypothesis that MT changed similarly between conditions following a 4-week strength phase. For changes in 1RM strength, the evidence favoured neither hypothesis (i.e. null vs. alternative). Of note, the mean difference between conditions was small [0.72 (4.3) kg]. 1RM training produces similar increases in strength as traditional training. Experiment 2 suggests that increases in muscle mass may not increase the 'potential' for strength gain. 1RM training produces similar increases in strength as traditional training. Experiment 2 suggests that increases in muscle mass may not increase the 'potential' for strength gain. Accumulating evidence indicates that serum- and glucocorticoid-inducible kinase 1 (SGK1) plays a role in the development of metabolic syndrome via a poorly understood mechanism. This study aimed to investigate the direct effect of SGK1 on insulin sensitivity in adipose tissue. We ectopically expressed or silenced SGK1 in adipocytes via lentiviral transfection, measured glucose uptake and evaluated insulin signalling using western blotting. In vivo insulin resistance was measured at the whole-body and adipose tissue levels in db/db mice treated with an inhibitor of SGK1. After 8 weeks of SGK1 inhibitor treatment, the serum insulin level andhomeostasis model assessment of insulin resistance index were significantly decreased, and AKT phosphorylation in adipose tissue was enhanced in db/db mice. Overexpression of constitutively active SGK1 in adipocytes in vitro decreased AKT phosphorylation and insulin-stimulated glucose uptake. Dexamethasone and oleic acid increased SGK1 expression and decreased AKT phosphorylation and insulin receptor substrate expression in adipocytes. Administration of an inhibitor of SGK1 or Lv-shSGK1 reversed the suppression of insulin s